<DOC>
	<DOCNO>NCT01480778</DOCNO>
	<brief_summary>Assessment pharmacodynamic profile drug Ciclo 21 ® , market União Química Farmacêutica Nacional S / A , compare drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda . Through modulation hormonal response ( inhibition pituitary ) evidence measurement serum LH FSH 28 day , well absence follicle formation demonstrate transvaginal ultrasound examination</brief_summary>
	<brief_title>Evaluation Ciclo 21® Effect ( Levonorgestrel + Ethinyl Estradiol ) Compared Nordette® .</brief_title>
	<detailed_description>secondary objective - Evaluation safety aspect medicine type , frequency intensity adverse event group 28 day trial . exploratory objective - Evaluation pharmacokinetics drug administer dosage serum hormone levonorgestrel ethinyl estradiol 28 day .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Comply study procedure , sign , initial date back , free , IC ; 2 . Women age 18 35 year , regardless race class ; 3 . Make use safe nonhormonal method contraception tubal ligation , nonhormonal IUDs condom , hysterectomised vasectomized sexual partner ; 4 . Examination BetaHCG negative ; 5. regular menstrual cycle every 24 32 day , least last three month ; 6. present normal Pap test ( current past 02 year ) ; 7 . Present vaginal examination find change interfere study ; 8. present level FSH , LH , estradiol TT normal menstrual cycle , well normal transvaginal sonographic report . 1 . Provide contraindication use steroid ; 2 . Use regular prediction drug interfere metabolism investigational product , antibiotic , anticonvulsant , anticoagulant hypoglycemic drug ; 3. smoker stop smoke less 12 month ; 4 . Diabetic ; 5 . Toxicdependent ; 6 . BMI &lt; 18 &gt; 25 ; 7. make use topical systemic sex hormone least two month start study ; 8 . Background personal family history thrombosis bleed disorder vascular disorder cardiovascular disease ; 9 . Laboratory test , gynecological ultrasound change , medical criterion ; 10 . Individuals allergy rheumatic disease indicate use corticosteroid medication ; 11. carry endocrine change , especially pituitary gonadal / advise use hormone ; 12. lesion abnormality suspect confirmed gonad . 13. personal family history breast cancer hormonedependent breast pathology ; 14. hypertension diabetes mellitus ( drug interaction COC hypoglycemic agent antihypertensive ) ; ) History nausea oral use COCs ; p ) Any condition may interfere discretion investigator study data well measurement study deleterious patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hormonal response , levonorgestrel , ethinyl estradiol</keyword>
</DOC>